|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 38.20 USD | +0.53% |
|
-2.55% | +26.49% |
Business description: Gedeon Richter
Number of employees: 11,155
Sales by Activity: Gedeon Richter
| Fiscal Period: December | 2021 (HUF) | 2022 (HUF) | 2023 (HUF) | 2024 (HUF) | 2025 (HUF) |
|---|---|---|---|---|---|
Pharmaceuticals - Women's Healthcare (WHC) | - | - | 256B | 286B | 329B |
Pharmaceuticals - Neuropsychiatry (CNS) | - | - | 206B | 243B | 265B |
Pharmaceuticals - General Medicines (GM) | - | - | 227B | 251B | 250B |
Pharmaceuticals - Pharma Other | - | - | 13.02B | 11.12B | 6.99B |
Pharmaceuticals | 505B | 656B | - | - | - |
Pharmaceuticals - Biotechnology (BIO) | - | - | 46.2B | 54.01B | 64.16B |
Other | 7.15B | 9.72B | 70.87B | 24.98B | 25.58B |
Wholesale and Retail | 134B | 155B | - | - | - |
Eliminations | -15.79B | -17.88B | -13.16B | -12.24B | -10.58B |
Geographical breakdown of sales: Gedeon Richter
| Fiscal Period: December | 2021 (HUF) | 2022 (HUF) | 2023 (HUF) | 2024 (HUF) | 2025 (HUF) |
|---|---|---|---|---|---|
Europe | 263B | 328B | 501B | 511B | 551B |
North America | - | - | 221B | 255B | 276B |
APAC | - | - | 43.07B | 48.62B | 54.71B |
Latin America | 17.6B | 27.88B | 31.68B | 35.53B | 38.31B |
Rest of The World | 31.24B | 36.5B | 8.26B | 6.71B | 9.05B |
China | 15.59B | 21.71B | - | - | - |
Hungary | 44.38B | 46.62B | - | - | - |
CIS (Commonwealth of Independent States) | 135B | 180B | - | - | - |
United States of America | 123B | 162B | - | - | - |
Executive Committee: Gedeon Richter
| Manager | Title | Age | Since |
|---|---|---|---|
Gábor Orbán
CEO | Chief Executive Officer | 47 | 2017-10-31 |
| Director of Finance/CFO | - | 2025-04-30 | |
Attila Szénási
COO | Chief Operating Officer | - | 2018-12-31 |
Istvan Greiner
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Robert Rethy
IRC | Investor Relations Contact | - | - |
Composition of the Board of Directors: Gedeon Richter
| Director | Title | Age | Since |
|---|---|---|---|
Erik Bogsch
CHM | Chairman | 78 | 2016-12-31 |
Szilveszter Vizi
CHM | Chairman | 90 | 2024-02-29 |
| Director/Board Member | 65 | 2012-04-25 | |
Gábor Orbán
BRD | Director/Board Member | 47 | 2017-03-31 |
Ilona Hardy
BRD | Director/Board Member | 70 | 2017-04-25 |
Anett Pandurics
BRD | Director/Board Member | 53 | 2018-04-24 |
Bálint Szécsényi
BRD | Director/Board Member | 51 | 2018-04-24 |
Péter Cserháti
BRD | Director/Board Member | 63 | 2020-04-27 |
Gal Krisztina
BRD | Director/Board Member | - | 2021-04-14 |
Livia Pavlik
CHM | Chairman | - | - |
Holdings: Gedeon Richter
| Name | Stocks | % | Valuation |
|---|---|---|---|
GEDEON RICHTER 1.93% | 3,601,971 | 1.93% | 152 M $ |
Company details: Gedeon Richter
Chemical Works of Gedeon Richter Plc
Gyömrõi út 19-21
1103, Budapest
+36 1 431 4000
http://www.richter.hu
Generic Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.62% | +2.33% | +12.10% | +87.89% | 47.71B | |
| -0.28% | +2.55% | +53.22% | +98.46% | 35.38B | |
| +0.15% | +6.61% | -4.15% | +45.55% | 12.32B | |
| +0.19% | +3.77% | +14.19% | +97.70% | 11.74B | |
| +0.57% | -0.57% | +37.80% | +122.46% | 9.02B | |
| -0.40% | +4.05% | +49.89% | -14.20% | 6.83B | |
| -1.20% | +0.83% | +28.00% | +240.35% | 6.53B | |
| -0.19% | +3.95% | -34.41% | +1.33% | 5.14B | |
| -2.31% | +3.28% | +24.03% | +117.40% | 4.31B | |
| Average | -0.45% | +3.58% | +20.07% | +88.55% | 15.44B | |
| Weighted average by Cap. | -0.37% | +3.29% | +24.22% | +89.76% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RICHTER Stock
- CHWGR Stock
- Company Gedeon Richter
Select your edition
All financial news and data tailored to specific country editions
